Advanced search
Publication Cover
Leukemia & Lymphoma Volume 59, 2018 - Issue 11
Submit an article Journal homepage
181
Views
5
CrossRef citations to date
0
Altmetric
Letter to the Editor

Significant impact of immunosuppression on the incidence of secondary malignancies following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with indolent B-cell neoplasms

Nathalie DenizonDepartment of Hematology, Centre Hospitalier Le Mans, Le Mans, France;
,
Alix Baugier de MaterreRothschild Hospital, Geriatric Department, Assistance Publique hôpitaux de Paris, Paris, France
,
Mustapha AlaniDepartment of Hematology, Centre Hospitalier Le Mans, Le Mans, France;
,
Habib GhnayaDepartment of Hematology, Centre Hospitalier Le Mans, Le Mans, France;
,
Jonathan FarhiDepartment of Hematology, Centre Hospitalier Le Mans, Le Mans, France;
,
Anne BesançonDepartment of Hematology, Centre Hospitalier Le Mans, Le Mans, France;
&
Kamel LaribiDepartment of Hematology, Centre Hospitalier Le Mans, Le Mans, France; Correspondence[email protected]
 show all
Pages 2711-2714 | Received 25 Dec 2017, Accepted 02 Mar 2018, Published online: 21 Mar 2018

References

  • Hallek M. Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2017;92:946–965.
  • Dreger P, Schetelig J, Andersen N, et al. Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents? Blood. 2014;124:3841–3849.
  • Salles G, Barrett M, Foa R, et al. Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience. Adv Ther. 2017;34:2232–2273.
  • Benjamini O, Jain P, Trinh L, et al. Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes. Leuk Lymphoma. 2015;56:1643–1650.
  • Morton LM, Curtis RE, Linet MS, et al. Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype. J Clin Oncol. 2010;28:4935–4944.
  • Cheson BD, Vena DA, Barrett J, et al. Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. J Clin Oncol. 1999;17:2454–2460.
  • Bertoli S, Sterin A, Tavitian S, et al. Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies. Oncotarget. 2016;7:85937–85947.
  • Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376:1164–1174.
  • Fischer K, Bahlo J, Fink AM, et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016;127:208–215.
  • Aksoy S, Arslan C, Harputluoglu H, et al. Malignancies after rituximab treatment: just coincidence or more?. J Buon. 2011;16:112–115.
  • Carney DA, Westerman DA, Tam CS, et al. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy. Leukemia. 2010;24:2056–2062.
  • Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000;343:1750–1757.
  • Colovic M, Suvajdzic N, Jankovic G, et al. Therapy-related myelodysplastic syndrome and acute myeloid leukemia in patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide. Biomed Pharmacother. 2011;65:319–321.
  • Falchi L, Vitale C, Keating MJ, et al. Incidence and prognostic impact of other cancers in a population of long-term survivors of chronic lymphocytic leukemia. Ann Oncol. 2016;27:1100–1106.
  • Sharman J, Mato A, Kay N, et al. Demographics by age group and line of therapy in chronic lymphocytic leukemia patients treated in US practices from the Connect CLL registry. Blood. 2014;124:3338.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.